T cell-rich tumors correlated with delayed recurrence or death and were associated with increased expression of Interleukin-2 (IL-2), IFNγ and lymphocyte-attracting chemokines within the tumor such as CXCL9 [113], CCL21, and CCL22 [5]. This evidence concerns the gene CCL22 and neoplasm.